TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
01 nov. 2018 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
TBIO.jpg
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
18 oct. 2018 07h30 HE | Translate Bio, Inc.
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq:...
TBIO.jpg
Translate Bio to Participate in the Leerink Partners Roundtable Series: Rare Disease & Oncology
25 sept. 2018 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio to Participate in Citi’s 13th Annual Biotech Conference
30 août 2018 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Second Quarter 2018 Financial Results and Highlights Recent Development and Corporate Achievements 
09 août 2018 16h17 HE | Translate Bio, Inc.
-- Initiated Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis ---- Established strategic mRNA vaccines partnership with Sanofi Pasteur ---- Completed initial public offering...
Translate Bio Announ
Translate Bio Announces Closing of Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for Infectious Diseases
09 juil. 2018 07h00 HE | Translate Bio, Inc.
LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...